Imunon (IMNN) Projected to Post Earnings on Thursday

Imunon (NASDAQ:IMNN) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Imunon Stock Performance

IMNN opened at $3.14 on Wednesday. The stock has a market cap of $9.64 million, a price-to-earnings ratio of -0.32 and a beta of 2.14. The firm’s fifty day moving average is $3.50 and its 200 day moving average is $4.46. Imunon has a fifty-two week low of $2.99 and a fifty-two week high of $41.22.

Hedge Funds Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. DRW Securities LLC lifted its holdings in Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 58,830 shares of the company’s stock after buying an additional 3,803 shares during the period. DRW Securities LLC owned about 1.92% of Imunon worth $224,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 4.47% of the company’s stock.

Analyst Upgrades and Downgrades

IMNN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research note on Thursday, January 22nd. Brookline Capital Acquisition reissued a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $232.50.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.